Showing 3061-3070 of 3196 results for "".
- AAD Releases New App to Aid Patients with Chronic Hiveshttps://practicaldermatology.com/news/aad-releases-new-app-to-aid-patients-with-chronic-hives/2458798/The American Academy of Dermatology (AAD) released its Chronic Hives Patient App, which offers tools and resources for chronic hives management. The free mobile app, developed with a grant from Novartis Pharmaceuticals Corp., can help patients learn more about their condition, find a doctor, trac
- Revance Reports Positive 6-Month Duration for RT002 in BELMONT Studyhttps://practicaldermatology.com/news/revance-reports-positive-6-month-duration-for-rt002-in-belmont-study/2458831/Revance Therapeutics, Inc., shared positive 24-week results from its multi-center BELMONT Phase 2 active comparator study of injectable RT002. The ongoing study for the treatment of glabellar lines in 268 subjects compared the safety, efficacy, and duration of effect of three doses of RT002
- Zwivel and CareCredit Team Uphttps://practicaldermatology.com/news/zwivel-and-carecredit-team-up/2458836/CareCredit, a provider of patient financing, and Zwivel, an online cosmetic consultation platform that enables cosmetic patients and doctors to interact prior to an in-office consultation, signed a marketing agreement enabling consumers to apply for a CareCredit health, wellness, and beauty credi
- FDA Accepts sNDA for Dalvancehttps://practicaldermatology.com/news/fda-accepts-snda-for-dalvance/2458849/The FDA accepted Allergan's supplemental New Drug Application (sNDA) to expand the label to include single-dose administration of DALVANCE® (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults caused by design
- Revance Therapeutics Initiates Phase 3 Clinical Trial of Botulinum Toxin Type A Topical Gel for Crow's Feethttps://practicaldermatology.com/news/revance-therapeutics-initiates-phase-3-clinical-trial-of-botulinum-toxin-type-a-topical-gel-for-crows-feet/2458857/Revance Therapeutics, Inc. has commenced dosing patients in the Phase 3 pivotal study to evaluate the safety and efficacy of its RT001 investigational topical drug product candidate for the treatment of lateral canthal lines, or crow’s feet. The Phase 3 trial will evaluate the safety and ef
- Radiesse from Merz Aesthetics Approved for Handshttps://practicaldermatology.com/news/radiesse-from-merz-aesthetics-approved-for-hands/2458934/Radiesse® from Merz Aesthetics received FDA approval for hand augmentation to correct volume loss in the dorsum of the hands. Radiesse® provides an immediate volumizing effect and can help to reduce the prom
- Survey Reveals Attitudes About Lip Healthhttps://practicaldermatology.com/news/survey-reveals-attitudes-about-lip-health/2458937/The majority of Americans suffer from dry and chapped lips, and 1 in 4 say that when their lips are chapped and flaky they don’t look attractive. Furthermore, close to 1 in 5 say their self-confidence goes down when their lips are chapped and flaky and, some even
- ASDS Releases Consensus Recommendations on Basal Cell Carcinomahttps://practicaldermatology.com/news/asds-releases-consensus-recommendations-on-basal-cell-carcinoma/2458947/An expert group of dermatologic surgeons appointed by the American Society for Dermatologic Surgery (ASDS) Board of Directors has developed the first-ever consensus recommendations on the treatment and management of basal cell carcinoma (BCC). According to the ASDS, the document is intend
- Cipher Pharmaceuticals Acquires Innocutishttps://practicaldermatology.com/news/cipher-pharmaceuticals-acquires-innocutis/2458969/Cipher Pharmaceuticals Inc. has acquired Innocutis Holdings LLC, a privately held specialty dermatology company, for US$45.5 million in cash. (All financial references are in U.S. dollars unless otherwise noted.) "This acquisition marks our commercial entry to the U.S. market an
- Aclaris Therapeutics' A-101 Achieves Positive Results in Clinical Trial for Seborrheic Keratosishttps://practicaldermatology.com/news/aclaris-therapeutics-a-101-achieves-positive-results-in-clinical-trial-for-seborrheic-keratosis/2458989/Aclaris Therapeutics, Inc.’s lead drug candidate A-10 demonstrated clinically and statistically significant improvements in removing seborrheic keratosis (SK) lesions on the face in its third Phase II clinical trial. The double-blind, vehicle-controlled Phase 2 clinical trial was designed t